The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice
Sign Up to like & getrecommendations! Published in 2020 at "Theranostics"
DOI: 10.7150/thno.44334
Abstract: Probody® therapeutics are recombinant masked monoclonal antibody (mAb) prodrugs that become activated by proteases present in the tumor microenvironment. This makes them attractive for use as Probody drug conjugates (PDCs). CX-2009 is a novel PDC… read more here.
Keywords: probody; drug; tumor targeting; 89zr immuno ... See more keywords